Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
benzinga.com/25/04/45105514/novartis-to-buy-us-kidney-drug-developer-regulus-therapeutics-for-around-800-million
Novartis AG (NYSE:NVS) agreed to acquire Regulus Therapeutics Inc. (NASDAQ:RGLS) on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.
The upfront cash portion of the consideration represents a premium of 274% to Regulus’ 60-day volume-weighted average stock…
This story appeared on benzinga.com, 2025-04-30 15:22:41.